Pain Therapeutics, Inc. Share Price Nasdaq
Equities
US69562K5065
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | 150M 11.92B | Capitalization | 989M 78.59B |
---|---|---|---|---|---|
Net income 2024 * | -96M -7.63B | Net income 2025 * | - 0 | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 6.6 x |
P/E ratio 2024 * |
-9.61
x | P/E ratio 2025 * |
-43.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.53% |
Managers | Title | Age | Since |
---|---|---|---|
Remi Barbier
CEO | Chief Executive Officer | 64 | 30/04/98 |
Eric Schoen
DFI | Director of Finance/CFO | 55 | 30/09/18 |
James Kupiec
CTO | Chief Tech/Sci/R&D Officer | - | 03/01/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Remi Barbier
CEO | Chief Executive Officer | 64 | 30/04/98 |
Robert Gussin
BRD | Director/Board Member | 86 | 28/02/03 |
Patrick Scannon
BRD | Director/Board Member | 76 | 06/12/07 |
1st Jan change | Capi. | |
---|---|---|
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |